Synnovation Therapeutics’ Post

Spoke to Cody Shandraw earlier this week about the ongoing FDA priority review for Lykos Therapeutics MDMA-assisted therapy, and the chances of it passing. He firmly believes if approved by the FDA, with a slated time period of early August, that would we could see the following .. “I think you could see a market move unlike anything for an industry throughout public markets history” Does it seem bold? Well think about what’s happened this year. atai Life Sciences $50m investment into Beckley Psytech. Cybin Inc raising $150m with a number of strategic biotech investors. MindMed and the $175m they raised after their ground breaking phase 2 results. Reunion Neuroscience raising $103m. Not to mention, Lykos raised $100m back in January. If approved, you’re only going to see the valuation of this company increase dramatically. Check our latest podcast in the comment section. Doug Drysdale Robert Barrow Payton Nyquvest Cosmo Feilding Mellen Florian Brand Christian Angermayer Lars Christian Wilde E. Matthew ("Whiz") Buckley Elemer Piros Daniel Carcillo Joe Caltabiano Rob Crocker Graham Farrell Michael Boughner Tyler Beuerlein Michael Tan Rick Doblin Michael B. Galloro, CPA Barrington Miller #psychedelics #psychedelic #psychedelicstocks #mentalhealth #stocks

We are delighted to share the outstanding performance of Ally Bridge Group, one of our top-performing fund managers in the life sciences sector, which has successfully executed its fourth liquidity event since September 2023. Specializing in late-stage private equity, Ally Bridge Group is dedicated to significant investments in groundbreaking life science innovations aimed at fulfilling critical medical needs, primarily within the U.S. MedTech, biotech, diagnostics, and telehealth industries. Our firm has consistently supported Ally Bridge's previous funds and takes pride in their recent achievements in the U.S., highlighted by four notable liquidity events within the last five months: 𝟭. 𝗖𝗚 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 [𝗖𝗚𝗢𝗡.𝗡𝗮𝘀𝗱𝗮𝗾]: Listed on January 25, 2024, this company focuses on oncolytic immunotherapy for bladder cancer. Its IPO was nearly 20 times oversubscribed, with shares initially offered at $19 and closing at $37.26 after opening at a 96% increase, valuing the company at $2.2 billion. https://lnkd.in/dkMXjz4r    𝟮. 𝗖𝗮𝗿𝗴𝗼 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 [𝗖𝗥𝗚𝗫.𝗡𝗮𝘀𝗱𝗮𝗾]: Listed in November 2023, it is a clinical-stage biotech firm developing next-generation cell therapies for cancer. The IPO price was $15.00 per share, with a recent closing at $22.01. 𝟯. 𝗥𝗮𝘆𝘇𝗲𝗯𝗶𝗼 𝗜𝗻𝗰 [𝗥𝗬𝗭𝗕.𝗡𝗮𝘀𝗱𝗮𝗾]: Listed in September 2023, specializing in targeted radiopharmaceuticals for cancer treatment, was acquired by Bristol Myers Squibb on December 26, 2023, at $62.5 per share, compared to its IPO price of $18.00. https://lnkd.in/g7bcEkiZ 𝟰. 𝗥𝗲𝗹𝗶𝗲𝘃𝗮𝗻𝘁: Invested in March 2023, this medical device company focuses on treating chronic lower back pain and was acquired by Boston Scientific on November 17, 2023. https://lnkd.in/dhjGUJAC Congratulations to all our clients who have participated in these ventures. We look forward to further deploying capital into Ally Bridge’s follow-on fund, 'ABG V'.

It's no secret that I'm a big believer that #biotech is the investment wave of the 2020s. So, am I surprised that CG Oncology's IPO soared by 96% on its first day? Well, a little! Some #investors have been slow to adopt the biotech wave—especially when it's a brand-new IPO. But CG's success could point to increased (and much-deserved) interest in the field. Time will tell if CG Oncology can live up to these expectations. But one thing is clear: biotech #investments are growing in popularity. And I expect that trend to continue for at least the next several years. https://loom.ly/GNf7vvQ

We are excited to announce the successful close of our £40.5 million Series A financing! We are very proud to welcome our new investors Pfizer Ventures LLC, who led the round, COLUMBUS VENTURE PARTNERS,S.G.E.I.C., S.A.U. and British Patient Capital. They were joined by our founding investor Advent Life Sciences, and seed investor Epidarex Capital, underlining strong blue chip confidence behind Curve Therapeutics' vision to transform the lives of patients by addressing disease targets which are intractable to conventional #drugdiscovery methods. The financing will enable Curve Therapeutics to turbocharge its Microcycle® discovery platform and advance its promising pipeline of assets with the potential to treat unmet clinical needs in a diverse range of diseases, including cancer. To learn more about the financing and our proprietary discovery platform, read the full press release here: https://lnkd.in/eRDFP2X6 #biotech #financing #investment

CTI Life Sciences Fund is excited to share that enGene, a CTI portfolio company, received $200M in an over-subscribed private placement financing round. This financing will give enGene the capital to complete the pivotal trial of EG-70, the best-in-class bladder cancer treatment. It will also allow the company to explore additional opportunities for EG-70 and potential new R&D programs. The financing included participation from new and existing investors, including Adagia Partners, Blue Owl Capital, Boxer Capital, LLC, Commodore Capital LP, Cormorant Asset Management, LP, Deep Track Capital, an affiliate of Deerfield Management Company, Foresite Capital, Janus Henderson Investors, Logos Capital, Lumira Ventures, Marshall Wace, Perceptive Advisors, Soleus Capital Management, L.P., Surveyor Capital (a Citadel company), VENROCK HEALTHCARE CAPITAL PARTNERS LP, and a large investment management firm. https://lnkd.in/gusdhZ6f

An exciting evolution for the world of psychedelic medicine 🌍 It's encouraging to see an organization like Helena (an org that believes problems caused by humans can be solved by humans) backing psychedelic medicine research and development 👏 From the recent Psychedelic Alpha coverage of the newly formed Lykos Therapeutics (formerly MAPS PBC), a quote from Helena founder Henry Elkus, "You cannot solve a problem without, as a prerequisite, human coordination... human empathy" #Psychedelics expand our awareness of ourselves & the impact we can have on the world around us. They give our brains an opportunity to think a little differently, to see things from a new point of view. Compounds like #mdma increase empathy 🤝 Coordination (to solve the problems we are collectively facing on a global scale) necessitates empathy.

Genetron Holdings Limited（Genetron Health） has announced it will go private through an acquisition by a group of investors led by its co-founder and CEO Sizhen Wang and CICC Healthcare Investment Fund which values the Chinese precision oncology platform at $126 million. The company’s US-listed American Depository Shares (ADSs) jumped 27% in early Thursday trading to $1.1950. Under the terms of the deal, holders of the company’s ADSs will receive $1.36 in cash per ADS, a 42% premium to the closing price on October 10. The merger is expected to close during the first quarter of 2024, subject to conditions including the approval of shareholders holding two-thirds of its shares. The company said members of the consortium and rollover shareholders represent roughly 59.7% of its shares. Genetron specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development. Contact the author at... More at #Proactive #ProactiveInvestors http://ow.ly/vG67104XzuP

💲𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁💲 Moving into the final part of this year and looking back at September there were some large investments made! The 5 biggest rounds of fundraising globally were: Generate:Biomedicines, raised $273M in Series C Nimbus Therapeutics, raised $210M in Private Equity Apollo Therapeutics, raised $226.5M in Series C Avalyn Pharma Inc., raised $175M in Series C Mariana Oncology, raised $175M in Series B That is only a handful of investments made, but September saw some incredibly strong numbers. Is it bringing hope that the market is shifting positively in the right direction? #investment #biotech #lifesciences

We have closed our £26m Series B follow-on financing. The round was led by new #investor Panakes Partners, joined by our existing investors Versant Ventures, Novartis Venture Fund, Forbion, Epidarex Capital and IP Group plc. The #investment will fund the Phase 2a #clinical #proofofconcept trial in #cysticfibrosis for our lead programme, ETD001. With first-in-class potential, ETD001 targets the ENaC #ionchannel in the airway epithelium, increasing the hydration and clearance of mucus to drive substantial improvements in #lungfunction. Funds will also support the progression of our other #preclinical programmes targeting the underlying mechanisms of mucus congestion in chronic #respiratory diseases. Alongside the financing, we are delighted to welcome Dr Rob Woodman, Partner at Panakes, to our #BoardofDirectors. Read the full press release here: https://rb.gy/kr6wf5

🎙In our newest #RunningThroughWalls episode, Nimish Shah speaks with Mirador Therapeutics Chairman and CEO Mark McKenna about the beginning of Mirador, what he learned from his time at Prometheus, what he values in a team and more. Listen here: https://vnrk.co/3KxobCR